Patient (pt) characteristics, treatment patterns, and outcomes in unresectable hepatocellular carcinoma (uHCC) treated with first-line (1L) systemic therapy in the United States (US).

被引：0
|
作者：
Tran, Nguyen H.
Soefje, Scott A.
Rangarajan, Nivedita
Purushotham, K.
Nadig, Mihika
Wagner, Tyler E.
Valerio, Stephen J.
Anderson, Rye
Olson, Jody C.
机构：
[1] Mayo Clin Rochester, Dept Oncol, Rochester, MN USA
[2] Mayo Clin, Dept Pharm, Rochester, MN USA
[3] Nference Inc, Cambridge, MA USA
[4] US Oncol Med Affairs AstraZeneca, Gaithersburg, MD USA
[5] AstraZeneca, US Oncol Care & Access, Gaithersburg, MD USA
[6] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.572
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：572 / 572
页数：1
相关论文
共 50 条
  • [1] Real-World Treatment Patterns and Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Receiving First-Line (1L) Therapy in the United States (US)
    Mato, Anthony R.
    Ravelo, Arliene
    MyTo, Tu
    Schuldt, Robert
    Biondo, Juliana M. L.
    BLOOD, 2021, 138
  • [2] Evaluation of first-line systemic treatments for unresectable hepatocellular carcinoma (uHCC): A network meta-analysis
    Zhi, W.
    Xu, F.
    Luo, J.
    Zhang, C.
    Huang, X.
    Han, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1310 - S1310
  • [3] REAL-WORLD CLINICAL CHARACTERISTICS AND TREATMENT PATTERNS AMONG PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC) AMENABLE TO LOCOREGIONAL THERAPY (LRT) IN THE UNITED STATES (US)
    Parikh, Neehar
    Wang, William
    Farid-Kapadia, Mufiza
    Kebede, Nehemiah
    Underwood, Dex
    Cai, Ling
    Stirnadel-Farrant, Heide
    Hu, Jenny
    Wang, Cindy
    Garcia-Reyes, Kirema
    HEPATOLOGY, 2024, 80
  • [4] ctDNA analysis of patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with lenvatinib (LEN) or sorafenib (SOR) as 1L therapy
    Evans, T. R. Jeffry
    Kudo, Masatoshi
    Cheng, Ann-Lii
    Wyrwicz, Lucjan S.
    Ngan, Roger Kc
    Blanc, Jean-Frederic
    Baron, Ari David
    Vogel, Arndt
    Ikeda, Masafumi
    Piscaglia, Fabio
    Qin, Shukui
    Hoshi, Taisuke
    Tamaki, Ryuji
    Funahashi, Yasuhiro
    Okpara, Chinyere E.
    Sagane, Koji
    Xing, Dongyuan
    Minoshima, Yukinori
    Finn, Richard S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] HEALTH RESOURCE UTILIZATION (HRU) AND COSTS FOR METASTATIC RENAL CELL CARCINOMA (MRCC) PATIENTS TREATED WITH FIRST-LINE (1L) SYSTEMIC THERAPY IN THE UNITED STATES
    Mhatre, S.
    Lin, S.
    Surinach, A.
    Vohra, R.
    Satram-Hoang, S.
    Simpson, J.
    Wallen, H.
    Ogale, S.
    Gong, J.
    Pal, S. K.
    George, D. J.
    VALUE IN HEALTH, 2016, 19 (07) : A755 - A755
  • [6] The combined role of patients (pts) gender and disease etiology on unresectable HCC (uHCC) first-line (1L) treatment outcome
    Cesario, S.
    Genovesi, V.
    Rimini, M.
    Tada, T.
    Suda, G.
    Shimose, S.
    Kudo, M.
    Finkelmeier, F.
    Yoo, C.
    Presa, J.
    Iavarone, M. A.
    Marra, F.
    Foschi, F. G.
    Tamburini, E.
    Lonardi, S.
    Piscaglia, F.
    Salani, F.
    Vivaldi, C.
    Gardini, A. Casadei
    Masi, G.
    ANNALS OF ONCOLOGY, 2024, 35 : S83 - S83
  • [7] Prevalence of medical conditions or comorbidities influencing first-line therapy in unresectable hepatocellular carcinoma in the United States
    Schuler, Tammy A.
    Kamble, Shital
    Desai, Kaushal
    Bland, Emily
    Dubrovsky, Leonid
    Feinberg, Bruce
    FUTURE ONCOLOGY, 2025, 21 (03) : 313 - 319
  • [8] Real-world treatment characteristics for first-line therapy (1L) of advanced hepatocellular carcinoma (HCC) in Canada and Europe.
    Gill, Sharlene
    Jaffe, Dena H.
    DeCongelio, Marc
    DuBell, Arnold N.
    Shi, Jing
    Wisniewski, Tami
    Thompson, Gwilym
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [9] Impact of BMI and Body Composition on First-line Systemic Treatment for Unresectable Hepatocellular Carcinoma
    Yamamoto, Takafumi
    Ito, Takanori
    Mizuno, Kazuyuki
    Yokoyama, Shinya
    Yamamoto, Kenta
    Imai, Norihiro
    Ishizu, Yoji
    Honda, Takashi
    Kawashima, Hiroki
    ANTICANCER RESEARCH, 2024, 44 (09) : 4101 - 4111
  • [10] Regorafenib plus nivolumab as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Multicenter phase 2 trial (RENOBATE)
    Yoo, Changhoon
    Ryoo, Baek-Yeol
    Kim, Hyung-Don
    Ryu, Min-Hee
    Kang, Beodeul
    Chon, Hong Jae
    Hong, Jung Yong
    Lim, Ho Yeong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
12345